FDA Approves Celgene and Acceleron's Treatment for Rare Blood Disease

FDA Approves Celgene and Acceleron's Treatment for Rare Blood Disease

Source: 
BioSpace
snippet: 

The U.S. Food and Drug Administration (FDA) approved Celgene and Acceleron Pharma’s Reblozyl for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions. The approval marks the first approved treatment in the United States for this condition.